title: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.
abstract: BACKGROUND
  Ovarian cancer tends to be chemosensitive and confine itself to the surface of the peritoneal cavity for much of its natural history. These features have made it an obvious target for intraperitoneal (IP) chemotherapy. Chemotherapy for ovarian cancer is usually given as an intravenous (IV) infusion repeatedly over five to eight cycles. Intraperitoneal chemotherapy is given by infusion of the chemotherapeutic agent directly into the peritoneal cavity. There are biological reasons why this might increase the anticancer effect and reduce some systemic adverse effects in comparison to IV therapy.
  
  
  OBJECTIVE
  To determine if adding a component of the chemotherapy regime into the peritoneal cavity affects overall survival, progression-free survival, quality of life (QOL) and toxicity in the primary treatment of epithelial ovarian cancer.
  
  
  METHODS
  We searched the Gynaecological Cancer Review Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2011, MEDLINE (1951 to May 2011) and EMBASE (1974 to May 2011). We updated these searches in February 2007, August 2010 and May 2011. In addition, we handsearched and cascade searched the major gynaecological oncology journals.
  
  
  METHODS
  The analysis was restricted to randomised controlled trials (RCTs) assessing women with a new diagnosis of primary epithelial ovarian cancer, of any FIGO stage, following primary cytoreductive surgery. Standard IV chemotherapy was compared with chemotherapy that included a component of IP administration.
  
  
  METHODS
  We extracted data on overall survival, disease-free survival, adverse events and QOL and performed meta-analyses of hazard ratios (HR) for time-to-event variables and relative risks (RR) for dichotomous outcomes using RevMan software.
  
  
  RESULTS
  Nine randomised trials studied 2119 women receiving primary treatment for ovarian cancer. We considered six trials to be of high quality. Women were less likely to die if they received an IP component to chemotherapy (eight studies, 2026 women; HR = 0.81; 95% confidence interval (CI): 0.72 to 0.90). Intraperitoneal component chemotherapy prolonged the disease-free interval (five studies, 1311 women; HR = 0.78; 95% CI: 0.70 to 0.86). There was greater serious toxicity with regard to gastrointestinal effects, pain, fever and infection but less ototoxicity with the IP than the IV route.
  
  
  CONCLUSIONS
  Intraperitoneal chemotherapy increases overall survival and progression-free survival from advanced ovarian cancer. The results of this meta-analysis provide the most reliable estimates of the relative survival benefits of IP over IV therapy and should be used as part of the decision making process. However, the potential for catheter related complications and toxicity needs to be considered when deciding on the most appropriate treatment for each individual woman. The optimal dose, timing and mechanism of administration cannot be addressed from this meta-analysis. This needs to be addressed in the next phase of clinical trials.
authors.affiliation: Ward K3 John Hunter Hospital, Hunter New England Centre for Gynaecological Cancer, Newcastle, Australia. Kenneth.Jaaback@hnehealth.nsw.gov.au.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Jaaback
authors.forename: Nick
authors.initials: N
authors.lastname: Johnson
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Lawrie
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral / Q000009:adverse effects / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents
references.citation: Ann Intern Med. 1982 Dec;97(6):845-51
references.pmid: 6890785
references.citation: Gynecol Oncol. 2009 Oct;115(1):81-85
references.pmid: 19596139
references.citation: Gynecol Oncol. 2006 Jan;100(1):27-32
references.pmid: 16368440
references.citation: Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203
references.pmid: 14656280
references.citation: Lancet. 2009 Oct 17;374(9698):1331-8
references.pmid: 19767092
references.citation: Cancer Chemother Pharmacol. 1978;1(3):161-6
references.pmid: 373916
references.citation: Gynecol Oncol. 1991 Feb;40(2):103-6
references.pmid: 2010101
references.citation: Cancer Chemother Pharmacol. 1990;25(6):389-94
references.pmid: 2311166
references.citation: Gynecol Oncol. 1994 Sep;54(3):338-44
references.pmid: 8088611
references.citation: J Clin Oncol. 2007 Feb 1;25(4):437-43
references.pmid: 17264340
references.citation: Stat Med. 1998 Dec 30;17(24):2815-34
references.pmid: 9921604
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1248-59
references.pmid: 11870167
references.citation: Gynecol Oncol. 2010 Mar;116(3):340-4
references.pmid: 19922987
references.citation: Gynecol Oncol. 2001 Apr;81(1):77-81
references.pmid: 11277654
references.citation: J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9
references.pmid: 12953086
references.citation: Gynecol Oncol. 1985 Jan;20(1):1-9
references.pmid: 4038390
references.citation: Int J Gynecol Cancer. 2009 Jul;19(5):834-7
references.pmid: 19574769
references.citation: Gynecol Oncol. 2000 Feb;76(2):157-62
references.pmid: 10637064
references.citation: J Gynecol Obstet Biol Reprod (Paris). 1986;15(5):671-6
references.pmid: 3760480
references.citation: N Engl J Med. 1996 Dec 26;335(26):1950-5
references.pmid: 8960474
references.citation: Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:29-32
references.pmid: 18336396
references.citation: J Am Med Assoc. 1955 Dec 31;159(18):1704-7
references.pmid: 13271133
references.citation: J Clin Oncol. 2001 Feb 15;19(4):1001-7
references.pmid: 11181662
references.citation: Gynecol Oncol. 2011 Aug;122(2):215-20
references.pmid: 21665254
references.citation: Oncology. 1999;56(4):291-6
references.pmid: 10343192
references.citation: Anticancer Res. 2009 Jul;29(7):2803-8
references.pmid: 19596965
references.citation: Cochrane Database Syst Rev. 2016 Jan 12;(1):CD005340
references.pmid: 26755441
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3194-200
references.pmid: 12860964
references.citation: Crit Rev Oncol Hematol. 1999 Aug;31(3):239-46
references.pmid: 10532198
references.citation: Curr Oncol. 2011 Apr;18(2):84-90
references.pmid: 21505599
references.citation: Int J Gynaecol Obstet. 2001 Jan;72(1):55-60
references.pmid: 11146078
references.citation: Gynecol Oncol. 2009 Sep;114(3):415-9
references.pmid: 19577277
references.citation: N Engl J Med. 2006 Jan 5;354(1):34-43
references.pmid: 16394300
references.citation: Jpn J Clin Oncol. 2011 Feb;41(2):278-82
references.pmid: 20937602